Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation

  • Delgado-Arija, Marta
  • Genovés, Patricia
  • Pérez-Carrillo, Lorena
  • González-Torrent, Irene
  • Giménez-Escamilla, Isaac
  • Martínez-Dolz, Luis
  • Portolés, Manuel
  • Tarazón, Estefanía
  • Roselló-Lletí, Esther
[EN] Background Cardiac fibroblast activation protein (FAP) has an emerging role in heart failure (HF). A paradoxical reduction in its levels in pathological conditions associated with acute processes has been observed. We aimed to identify FAP cardiac tissue expression and its relationship with the main cardiac fibrosis-related signaling pathways, and to compare plasma FAP levels in acute and chronic HF patients. Methods Transcriptomic changes were assessed via mRNA/ncRNA-seq in left ventricle tissue from HF patients (n¿=¿57) and controls (n¿=¿10). Western blotting and immunohistochemistry were used to explore FAP protein levels and localization in cardiac tissue. ELISA was performed to examine plasma FAP levels in acute HF (n¿=¿48), chronic HF (n¿=¿15) and control samples (n¿=¿7). Results FAP overexpression in cardiac tissue is related to the expression of molecules directly involved in cardiac fibrosis, such as POSTN, THBS4, MFAP5, COL1A2 and COL3A1 (P¿<¿0.001), and is directly and inversely related to pro- and antifibrotic microRNAs, respectively. The observed FAP overexpression is not reflected in plasma. Circulating FAP levels were lower in acute HF patients than in controls (P¿<¿0.05), while chronic HF patients did not show significant changes. The clinical variables analyzed, such as functional class or etiology, do not affect plasma FAP concentrations. Conclusions We determined that in HF cardiac tissue, FAP is related to the main cardiac fibrosis signaling pathways as well as to pro- and antifibrotic microRNAs. Additionally, an acute phase of HF decreases plasma FAP levels despite the upregulation observed in cardiac tissue and regardless of other clinical conditions., This work was supported by the National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III [Projects: PI20/01469 and PI20/00071 co-funded by European Union; Miguel Servet contracts: CP18/00145 co-funded by European Union, European Social Fund (ESF) The ESF invests in your future and CP21/00041 co-funded by European Union; contract FI21/00186 and FI21/00034]; Consorcio Centro de Investi&#8209; gación Biomédica en Red [CIBERCV, under Grant CB16/11/00261]; Ministry of Universities and the European Recovery, Transformation and Resilience Plan (PRTR, Next Generation EU) [ Ayuda Margarita Salas para la formación de jóvenes doctores : contract: MS21-162]; Ministry of Science and Innovation (MCIN, 10.13039/501100011033) and State Investigation Agency (AEI) [Project CNS2022-135769] co-funded by European Union Next Generation EU and PRTR; Conselleria de educación, universidades y empleo [Project CIA&#8209; ICO/2022/246, contract CIACIF/2022/429].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Methylome-driven regulation of miRNA expression and its relationship to cardiac dysfunction in idiopathic dilated cardiomyopathy

  • Delgado-Arija, Marta
  • Gallego-Martínez, Alex
  • González-Torrent, Irene
  • Pérez-Carrillo, Lorena
  • Benedicto-Marrero, Carlota
  • Juan Bodí-Miret
  • Portolés, Manuel
  • Roselló-Lletí, Esther
  • Tarazón, Estefanía
[EN] Background Idiopathic dilated cardiomyopathy (iDCM) is a multifactorial disease with a complex pathogenesis involving diverse molecular mechanisms. Among these, epigenetic mechanisms, including both DNA methylation and microRNAs (miRNAs)-mediated regulation, play an important role in determining the disease phenotype. However, the interplay between the DNA methylome and the miRNA transcriptome in iDCM remains largely unexplored. Methods We conducted a cross-cohort multiomic integrative analysis of left ventricular (LV) tissue samples from iDCM patients and control (CNT) donors. DNA methylation profiling was performed using the Infinium MethylationEPIC BeadChip, whereas ncRNA-seq was used to assess transcriptomic changes. Results We identified a subset of three miRNAs exhibiting both differential methylation in their promoter regions and differential expression in their primary and mature forms. Notably, the miRNA hsa-miR-433-3p (r¿=¿0.671, p¿<¿0.01), which is involved in fibrotic pathways, appear to be significantly correlated with the left ventricular ejection fraction (LVEF), an established echocardiographic marker of cardiac function. Conclusions This study enhances our understanding of the epigenetic mechanisms shaping the miRNA transcriptomic landscape in iDCM, suggesting potential roles for these miRNAs in cardiac dysfunction and myocardial fibrosis., This work was supported by the National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III (Projects: PI20/00071, PI24/00088, PI24/01310) co-funded by European Union; Miguel Servet contract: CP21/00041 co-funded by European Union; contract FI21/00186]; Consorcio Centro de Investigación Biomédica en Red [CIBERCV, under Grant CB16/11/00261]; Ministry of Science and Innovation (MCIN,https://doi. org/10.13039/501100011033) and State Investigation Agency (AEI) (Project CNS2022-135769 and CNS2024-1544396) co-funded by European Union NextGeneration EU and the European Recovery, Transformation and Resilience Plan (PRTR); Conselleria de Educación, Universidades y Empleo (Project CIA&#8209;ICO/2022/246, contract CIACIF/2022/429).